Last edition
News about "Angelika Jahreis"
Novartis' Remibrutinib Shows Positive Phase III Results in Chronic Inducible Urticaria
Pivotal RemIND trial meets primary endpoint across three major CIndU subtypes, positioning oral remibrutinib as a potential first targeted therapy for inducible chronic hives.
Angelika Jahreis | 19/02/2026 | By News Bureau | 141
Novartis' Ianalumab Receives FDA Breakthrough Therapy Designation for Sjogren's Disease
The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s disease, accelerating its review as a potential first targeted treatment, with global filings planned from 2026.
Angelika Jahreis | 19/01/2026 | By News Bureau | 180
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy